logo

TXG

10x Genomics·NASDAQ
--
--(--)
--
--(--)
7.81 / 10
Outperform

TXG's fundamental score of 7.8/10 reflects strong cash flow from operations relative to revenue (19.98) and a high net profit attributable to shareholders ratio (100%). However, negative net income-revenue (-0.1668) and low net profit margin (-5.72%) indicate profitability challenges. Year-over-year revenue growth of 6.96% shows momentum, but the company operates in a negative earnings context, placing it in performance group 1 for Net income-Revenue with a historical one-month return of -0.69%. Overall, the fundamentals are favorable but not without risk.

Fundamental(7.81)SentimentTechnical

Analysis Checks(9/10)

Revenue-MV
Value-0.25
Score3/3
Weight28.30%
1M Return3.41%
Net profit attributable to parent company shareholders / Net profit (%)
Value100.00
Score2/3
Weight-11.32%
1M Return-1.63%
Total operating revenue (YoY growth rate %)
Value6.96
Score2/3
Weight-1.11%
1M Return-0.16%
Net cash flow from operating activities / Operating revenue (%)
Value19.98
Score3/3
Weight13.50%
1M Return1.58%
Net income-Revenue
Value-0.17
Score1/3
Weight-5.05%
1M Return-0.69%
Net profit margin (%)
Value-5.72
Score2/3
Weight6.81%
1M Return0.90%
Current assets turnover ratio
Value0.77
Score2/3
Weight1.99%
1M Return0.26%
EBIT / Total operating revenue (%)
Value-7.94
Score2/3
Weight8.48%
1M Return1.12%
Asset-MV
Value-0.50
Score3/3
Weight50.24%
1M Return5.62%
Net profit / Total operating revenue (%)
Value-5.72
Score2/3
Weight8.16%
1M Return1.07%
Is TXG undervalued or overvalued?
  • TXG scores 7.81/10 on fundamentals and holds a Discounted valuation at present. Backed by its -3.65% ROE, -11.89% net margin, -30.86 P/E ratio, 3.00 P/B ratio, and 58.55% earnings growth, these metrics solidify its Outperform investment rating.